Something is Rotten in the State of Denmark
Danish Scientists Find Negative Vaccine Efficacy Against Omicron Variant Three Months After Vaccination
Government scientists at the Department of Infectious Disease Epidemiology and Prevention of the Statens Serum Institut of the Danish Ministry of Health in Copenhagen, Denmark have published data showing negative vaccine efficacy against the Omicron Variant in people vaccinated more than three months ago.
Negative vaccine efficacy means that a vaccinated person is more likely to be infected than an unvaccinated person.
The data shows that between 91 and 150 days after full vaccination, the efficacy of the Pfizer COVID-19 vaccine is -76.5% against the Omicron variant, while the efficacy of the Moderna vaccine is -39.3%.
This is corroborated by a recent report from the Danish Ministry of Health that shows the Omicron Variant preferentially infecting the “fully vaccinated” (2 doses).
According to the latest data from the the Danish Health Authority: 18.1% of the population is unvaccinated, 4.3% have received one dose, 36.7% have received two doses, and 40.5% have received three doses (e.g. two doses plus a booster).
The 36.7% of “fully vaccinated” Danes that only have two doses of the COVID-19 vaccine accounted for 79% of Omicron cases and 65.3% of cases due to other variants between November 22nd and December 16th.
In contrast, the 18.1% of Danes who aren’t vaccinated only accounted for 8.5% of Omicron cases, and 22.9% of cases due to other variants during the same period of time.
People with two doses of the vaccine were more likely to get COVID than people who hadn’t taken the vaccine at all.
This isn’t the only data that shows negative vaccine efficacy occurring several months after primary vaccination. A large study conducted by researchers at Umeå University in Sweden, before the emergence of the Omicron variant, tracked the efficacy of the Pfizer, Moderna, and AstraZenica COVID-19 vaccines over 9 months. It found waning immunity followed by negative efficacy starting at about the 8 month mark.
The Swedish data and the Danish data match. The Danish scientists calculated that vaccine efficacy against the Delta variant was 53.8% for Pfizer, and 65.5% for Moderna, between 91 and 150 days after vaccination. That matches the 150 day mark of this graph from the Swedish study very closely.
The Swedish data also shows vaccine efficacy against severe illness decreases over time, but not as quickly. Not enough time has elapsed to know if the vaccine might eventually increase a person’s risk of developing severe COVID-19.
What this shows is that the COVID-19 vaccines protect you very well for several months, but after that you’re more likely to get COVID than if you hadn’t taken the vaccine at all — unless you get a booster every few months.
The Danish study notes that from 1 to 30 days after receiving a booster, Pfizer’s efficacy is restored to 81.2% for Delta and 54.6% for Omicron while Moderna is 82.8% for Delta and unknown for Omicron.
The long term side effects of these vaccines is unknown. To this day there is a disclaimer on all of Pfizer’s press releases that says: “Serious and unexpected side effects may occur. The possible side effects of the vaccine are still being studied in clinical trials.”
More side effects have been reported to the CDC’s Vaccine Adverse Event Reporting System (VAERS) for COVID-19 vaccines than have been reported for every other vaccine combined since the database was first established in 1990.
The good news is that the Omicron variant seems significantly less virulent than any of the previous variants. A strong spike in Omicron cases in South Africa (where the variant was first discovered) has not translated into a corresponding spike in deaths.
South African health authorities report that “the majority of patients in the COVID wards have not been oxygen dependent. SARS-CoV-2 has been an incidental finding in patients that were admitted to the hospital for another medical, surgical or obstetric reason.”
The most common symptoms reported by people infected with the Omicron variant in London, England are: runny nose, headache, fatigue, sneezing, and sore throat. The loss of taste, shortness of breath, and fever common in previous variants is largely absent with Omicron.
Researchers at the University of Hong Kong have found that the Omicron variant replicates at a rate 70 times greater than the Delta variant in the upper respiratory tract, but 10 times less in the lower respiratory tract. This may explain why it is more contagious, but less deadly than than past variants.
If we’re lucky, SARS-CoV-2 continues down this path and evolves into another endemic coronavirus that causes little more than a common cold — just like the other 4 endemic coronaviruses that commonly infect humans: 229E, NL63, OC43, and HKU1. Then we can shelve these vaccines for good.